9f978634-637c-472f-a588-6f4bb2fb121f	Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial.
claustrophobia	HP:0025253	26-40
20b34e62-97c2-4ca0-bb1d-7824dab0b8bb	There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial 
size	PATO:0000117	61-65
893a5337-2aa9-4a87-a020-4c2f03cd4aea	the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation.
age	PATO:0000011	59-62
age	PATO:0000011	106-109
range	LABO:0000114	110-115
d401affc-f081-4eee-bd61-d109cc88f6de	Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time
time	PATO:0000165	114-118
791790a6-187b-4e4b-be5f-9e5304e9ec2c	HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial
duration	PATO:0001309	145-153
b95b7438-ec16-4d4d-826d-5891e7982b36	There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial.
anorexia	HP:0002039	22-30
hypothermia	HP:0002045	32-43
hallucinations	HP:0000738	47-61
4988cb16-7dbb-4847-84e0-4a7957b32c72	a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial
patient	HADO:0000008,OAE:0001817	2-9
organ	UBERON:0000062	31-36
month	UO:0000035	64-69
excluded	HP:0040285	103-111
e244fc3a-53b3-4158-99c5-a45afc726af6	Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial.
allergy	HP:0012393	29-36
allergy	HP:0012393	147-154
cephalosporin	CHEBI:23066	40-53
levofloxacin	CHEBI:63598	158-170
celecoxib	CHEBI:41423	174-183
result	BAO:0000179	194-200
56530063-b408-47f2-8421-6be825f5559c	The Interventions in the primary trial are administered through different routes.
d3379655-55b7-4e58-88c2-c3cd3e8cb557	 Women with Newly diagnosed stage IV breast cancer, confirmed as ER+ Considering a mastectomy are eligible for the primary trial and the secondary trial
breast cancer	DOID:1612	37-50
7bf988b4-5e6f-41c4-bef6-7b3549dd58d9	Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial.
breast adenocarcinoma	DOID:3458	47-68
84915e35-a8c9-4d26-ad09-4b1df48a6df8	the secondary trial and the primary trial results contain completely different outcome measures 
64df451c-f868-49e6-9b4e-a325e62ce837	the primary trial participants do not receive any vaccines
dc4765a3-6168-4594-969b-3ce5ea7dc02a	Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934
9c2ca035-d531-4d44-876e-6ed9f2d3f76b	the secondary trial and the primary trial use different units of measure in their results.
7238ddd4-eade-4b88-8933-0c3df5be9875	There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results.
group	CHEBI:24433	62-67
group	CHEBI:24433	111-116
group	CHEBI:24433	129-134
aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3	Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression 
tamoxifen	CHEBI:41774	29-38
204d5293-d6e5-452a-8961-3b76d6be35c9	Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare.
time	PATO:0000165	48-52
group	CHEBI:24433	209-214
4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10	there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial
6d0812b9-f9bd-4cd6-82aa-9c272eba23be	Patients in the primary trial and the secondary trial suffered Thromboembolic events.
fd0fa999-2f1c-400d-977d-2d45dd9c358c	 intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously.
571d4650-e64b-4cb2-b719-0d7064e51745	in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy
hypertension	HP:0000822,DOID:10763	99-111
4437aa5b-4b4e-4eb4-a258-e7f17dc8f363	candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial
d7abbd7d-a767-49c0-bc99-1c28074eac21	Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae
54c7e880-a1bf-4206-9573-1c994932ba15	Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds.
radiotherapy	OAE:0000235	43-55
neuropathy	DOID:870	131-141
f9f0ba74-16e0-4790-afa0-b7616b256e5e	the secondary trial candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial
condition	PDRO:0000129	65-74
412583db-ce19-451d-a804-3837e4dcaea3	Coronary artery stenosis are the most common AE recorded in the primary trial
coronary artery stenosis	HP:0005145	0-24
bca4c94d-4a49-4e05-82ed-0d5c9707685b	The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs.
drug	CHEBI:23888	59-63
drug	CHEBI:23888	143-147
97acf304-2707-4a1b-81e7-339fde2ed0ee	patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial
dementia	HP:0000726,DOID:1307	30-38
dementia	HP:0000726,DOID:1307	48-56
mixed	BAO:0002107	42-47
21a5f296-5b3c-4860-be64-77ffb8f76501	Both cohorts of the primary trial contained the same number of participants
8d27bb53-e66e-4eab-bea4-0597fd5760b5	Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial.
history	BFO:0000182	21-28
breast	UBERON:0000310	71-77
dc60304d-6fd2-4b12-9108-b5ce78454d42	There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial
328417f9-8f45-4114-82d7-9396b6bc578e	Patients in the primary trial will need to receive one single injection on day 8 of the study.
day	UO:0000033	75-78
40d84c7b-e126-4d6f-9588-eb9c385ca716	Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias.
group	CHEBI:24433	0-5
b685be77-9c55-4948-99cc-2a249739a233	Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial.
result	BAO:0000179	42-48
5fbee4f6-43fc-45a7-88c4-3dcd5ff21053	A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial
patient	HADO:0000008,OAE:0001817	2-9
carcinoma	HP:0030731,DOID:305	42-51
8127d46a-3a48-4173-8d00-75e949755a74	Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial.
gabapentin	CHEBI:42797	21-31
year	UO:0000036	61-65
result	BAO:0000179	72-78
576967ff-d2bb-4d1c-b2a1-8516ceb7a519	In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily.
memantine	CHEBI:64312	54-63
fd334e71-2bbe-4138-b578-2ab848686045	CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial.
a72ddea5-ee4b-4895-bd8c-10b4a143c3f8	0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE.
6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546	cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV
enzalutamide	CHEBI:68534	46-58
d1118512-9c0b-4480-ab67-d4e0c7de390d	Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision
pulmonary embolism	HP:0002204,DOID:9477	30-48
excluded	HP:0040285	77-85
d35e9b96-20fc-4778-a7db-e87c861c4938	More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study
breast	UBERON:0000310	104-110
lymph	UBERON:0002391	124-129
25b01c06-612c-4cfb-b30b-50ebe4d98750	Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare.
time	PATO:0000165	48-52
group	CHEBI:24433	87-92
group	CHEBI:24433	124-129
group	CHEBI:24433	189-194
1a76bce8-07e2-4b30-adc8-3c095f0d62b3	At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial
23f84ae0-fd01-4799-8872-118e22a015e8	Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia
affected	HP:0032320	45-53
pancreatitis	HP:0001733,DOID:4989	85-97
cholelithiasis	HP:0001081,DOID:10211	99-113
pain	HP:0012531	123-127
neutropenia	HP:0001875,DOID:1227	140-151
c2aea351-6ce5-4d26-9ba5-2632c6367b93	at least one patient in the primary trial suffered several different adverse events
patient	HADO:0000008,OAE:0001817	13-20
388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7	Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream.
acupuncture	OAE:0002430	0-11
lymphedema	HP:0001004,DOID:4977	70-80
testosterone	CHEBI:17347	113-125
5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8	The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial
eyelid	UBERON:0001711	73-79
chest pain	HP:0100749	127-137
455d059c-c3c4-4a09-be0d-a14b9568a0d2	cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+
6d37ed53-a6e4-403e-8b93-9954a6486dbc	laser-assisted fluorescence angiography is used for both interventions in the primary trial.
e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe	2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction 
acute myocardial infarction	DOID:9408	93-120
41a0138d-7084-40d9-99ae-24db9e84acce	the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes.
median	BAO:0002174	141-147
sleep	GO:0030431	148-153
time	PATO:0000165	154-158
11cb71ed-1304-42f0-b416-3679c3e9e1b3	Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy
part of	BAO:0090002,BFO:0000050	68-75
radiotherapy	OAE:0000235	144-156
6ddf4b5b-69e2-46e1-b032-69c3173fd8ef	the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place.
month	UO:0000035	27-32
9349c7c8-7771-4dfc-8981-3c8d84ac5236	Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial.
ductal carcinoma in situ	HP:0030075,DOID:0060074	24-48
4e91cee2-910e-4f08-8a85-1f13545391c3	Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer.
cancer	DOID:162	110-116
18c281a1-43bd-47f5-9534-feddfcf0a282	Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs
doxorubicin	CHEBI:28748,BAO:0000639	72-83
cyclophosphamide	CHEBI:4026	88-104
frequency	HP:0040279	138-147
dd3d2183-d062-41ed-af63-ae475f2246ec	In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants.
711fdd40-52ec-401c-90fc-5a11de547ab6	eating disorders were not common for the primary trial candidates
49b3b463-a496-404a-a3a5-07cd7d4aaa92	Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial.
female	PATO:0000383	5-11
condition	PDRO:0000129	91-100
43b9c2c8-0785-4885-901b-91a1f893858f	The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736.
ibrutinib	CHEBI:76612	148-157
43989f85-a059-4dc7-a805-16e081706b2f	the primary trial and the secondary trial have 0 recorded adverse events.
282a33db-aed6-4daa-bea6-299f424914bb	over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period
646691ba-ad29-479f-81dc-131d9710c23b	Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial.
brainstem	UBERON:0002298	48-57
result	BAO:0000179	63-69
a0c1da21-1e1f-493b-81e9-4ef133c20090	The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial.
adverse event	OAE:0000001	16-29
439b1eca-f583-4a2b-bd8e-0baae97b4c15	Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study.
pain	HP:0012531	64-68
e12e5ed1-9a64-4183-9b9d-419e6679ab3d	Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial.
73849f1e-31c6-40c5-ab5c-35d0990ceac2	Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial.
ductal carcinoma in situ	HP:0030075,DOID:0060074	34-58
excluded	HP:0040285	100-108
f53c5344-36d7-459f-9f84-300e19decced	All Patients receiving the placebo intervention in the primary trial experienced emesis 
77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2	Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial.
cancer	DOID:162	4-10
patient	HADO:0000008,OAE:0001817	11-18
epilepsy	DOID:1826	41-49
anemia	HP:0001903,DOID:2355	76-82
99433bba-fce5-4b0a-a076-1f699b51472d	several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention
part of	BAO:0090002,BFO:0000050	91-98
135763e3-70fd-478d-991c-717d6ed55bb3	cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often.
6cbfc99b-6531-412f-bd30-b4a803983831	the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place.
week	UO:0000034	27-31
6a3053ef-4495-4c18-9da7-68cf5ed254e0	Every patient in the primary trial is receives a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray during radiation therapy
patient	HADO:0000008,OAE:0001817	6-13
fentanyl	CHEBI:119915	75-83
217b0362-9dd0-4f10-8ca5-c097688bb738	There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial.
nausea	HP:0002018	50-56
d88235dd-c37b-4971-9c1f-42b282ff41c1	Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent.
cancer	DOID:162	22-28
e6bbed17-0fdf-4008-b56e-4d901490ce1a	the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1.
f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9	All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events.
sunitinib	CHEBI:38940	41-50
adverse event	OAE:0000001	128-141
adverse event	OAE:0000001	211-224
8393ad3d-8521-4316-b69e-64910d8af5e7	the secondary trial and the primary trial report results using the same Unit of Measure.
cca11232-84c4-44e1-89f1-b57b28643dce	the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts.
cb36e435-6dc9-4e7b-939b-9da6ceef2a49	The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis.
trabectedin	CHEBI:84050	16-27
7ce21c0f-ad55-4ff7-a180-5e418fe9afc8	Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial.
cancer	DOID:162	22-28
42c38d71-6a83-4967-ad81-ec38c6b5aafd	cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1
enzalutamide	CHEBI:68534	64-76
6c5ebc06-00c4-4cf5-8912-93972ed5a49b	Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria.
radiotherapy	OAE:0000235	43-55
neuropathy	DOID:870	131-141
32cc173a-b271-47c9-997d-df17ce1c7494	None of the individual adverse event types recorded in the primary trial affected more than one patient
adverse event	OAE:0000001	23-36
affected	HP:0032320	73-81
patient	HADO:0000008,OAE:0001817	96-103
b742bc02-cd24-4ae7-b8b8-2a57bbd60d14	Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial
history	BFO:0000182	24-31
adenocarcinoma	DOID:299	98-112
stroke	HP:0001297,DOID:6713	114-120
transient	HP:0025153	122-131
abscess	HP:0025615	164-171
334b5f86-50c5-4711-994d-31ed67dd4282	women aged 18 or older are eligible for the secondary trial and the primary trial
04178e95-d808-4a96-ab85-61eb52c17720	a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event.
sunitinib	CHEBI:38940	36-45
adverse event	OAE:0000001	123-136
18d3b58f-42ca-4178-adb6-4a5f0c9fafde	None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks.
pain	HP:0012531	64-68
cfa6601b-af52-4eee-883c-89d42b73e02b	the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial.
anemia	HP:0001903,DOID:2355	43-49
pneumonia	HP:0002090,DOID:552	51-60
f58fda4c-f4fd-44a7-8a0f-5d3a16929709	one patient in the primary trial had an incident where a surgical incision reopened after the surgery.
patient	HADO:0000008,OAE:0001817	4-11
surgery	OAE:0000067	94-101
e52afcaa-e5d8-4a1f-ae39-8572a64b0aee	The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group.
group	CHEBI:24433	19-24
group	CHEBI:24433	146-151
week	UO:0000034	109-113
zoledronic acid	CHEBI:46557	125-140
96042d49-2f5a-44af-8899-2d5ba24c0f6f	less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products
587e611a-9c3b-4557-b3ca-56a7dcc6ce1b	In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110.
armodafinil	CHEBI:77590	46-57
ea3a7d64-b464-4633-a198-794a4a45b201	Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average.
tamoxifen	CHEBI:41774	41-50
surgery	OAE:0000067	86-93
surgery	OAE:0000067	130-137
breast cancer	DOID:1612	116-129
58165e03-4aa6-4d0c-8256-dbc92ee900c4	CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle
capecitabine	CHEBI:31348	0-12
day	UO:0000033	43-46
day	UO:0000033	115-118
patient	HADO:0000008,OAE:0001817	57-64
fa7b34e2-75e6-4bc4-a154-99be5bd6b381	Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial
7b9338a5-d3a8-405f-a197-736caf32c455	More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial.
palpitations	HP:0001962	5-17
8f078a17-14cd-4bbc-a9b6-b377ffa077b5	There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial
adverse event	OAE:0000001	48-61
2d36fa83-b68c-420e-873f-e69374d0741f	the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time.
lenalidomide	CHEBI:63791	39-51
lapatinib	CHEBI:49603	85-94
time	PATO:0000165	178-182
6e1489a6-3a42-4b52-b690-fb1dd8892749	The all recorded Aes in the primary trial occurred to cohort 1 patients
de6b5ea7-b593-43b7-8fe0-358991878e86	Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial.
fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c	In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110.
armodafinil	CHEBI:77590	46-57
827af363-cfd3-4233-9029-e8c7e053c661	There were more adverse events observed in the secondary trial than in the primary trial.
3c9a4b79-1f51-477a-a5b6-b69f76aeedf8	the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy
breast	UBERON:0000310	123-129
breast	UBERON:0000310	189-195
surgery	OAE:0000067	199-206
98b04dac-b155-4afd-8855-03ed818df5d9	We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial.
7eeeed55-fe37-47ae-be62-e50557ccaed1	Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors.
cbc96b9d-b39c-4fbe-b8a7-e7df7490881b	13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases
breast cancer	DOID:1612	55-68
2a05996c-d5fb-4aa8-9654-fb1d27180888	Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim.
neutropenia	HP:0001875,DOID:1227	56-67
da24d6fd-1363-489b-ac5a-f44dbe622c5d	Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial.
excluded	HP:0040285	25-33
437d5311-f0fd-4d61-82a2-5db0d07415f6	the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein
tube	BAO:0010014,UBERON:0000025	137-141
inserted	BAO:0000641	142-150
vein	UBERON:0001638	158-162
af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2	African-american patients can participate in the primary trial.
2bd78232-4872-4d66-ade9-836190b86e1d	A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial
patient	HADO:0000008,OAE:0001817	2-9
meningitis	HP:0001287,DOID:9471	38-48
80a26581-a95c-4c22-864f-93425b1fc165	The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.
cancer	DOID:162	133-139
4c926c31-8786-47b0-a032-1d59f759bca5	the primary trial and the secondary trial adminster their interventions orally.
62384871-8eb2-414b-8cc9-e756a188e19e	the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day
mtd	BAO:0001248	56-59
mtd	BAO:0001248	97-100
day	UO:0000033	163-166
a6e81477-f863-4a83-9007-fd2f1f5c6781	Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention.
breast cancer	DOID:1612	0-13
cancer	DOID:162	7-13
cancer	DOID:162	38-44
2312576f-7c8d-4fcd-80e8-42cf3d81dd04	cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel
eribulin	CHEBI:63587	55-63
8f4d4e78-5e46-47b6-865c-ad6b689d69e0	Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial.
chest pain	HP:0100749	75-85
a8268e5e-d758-4dcf-8dd9-78c2016bc7f6	Both the primary trial cohorts receive pre-operative Dexamethasone
dexamethasone	CHEBI:41879	53-66
d53cf5fe-1104-4b05-886c-bb5499cdc047	All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial.
musculoskeletal system	UBERON:0002204	76-98
1bd849aa-409c-4214-a930-4d187a645466	cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly.
frequency	HP:0040279	85-94
a5415a49-0b04-4f8f-a7ec-a8c276b2cf64	There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial.
5578e4a3-95d9-4803-8d13-b9c0276f92e0	Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency
doxorubicin	CHEBI:28748,BAO:0000639	72-83
cyclophosphamide	CHEBI:4026	88-104
frequency	HP:0040279	138-147
5e92a3fd-5ffa-49db-9978-897321839068	Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy.
539bf07d-199d-4c9b-af16-5f314962bcfc	Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin.
patient	HADO:0000008,OAE:0001817	10-17
patient	HADO:0000008,OAE:0001817	148-155
00831e0c-eaad-4fe9-a791-f105815fa215	Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial
severe	HP:0012828	24-30
insomnia	HP:0100785	31-39
excluded	HP:0040285	44-52
0a266c52-2a4e-4aed-a04c-85c148f2cd41	the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort.
capecitabine	CHEBI:31348	91-103
4e5a04a1-2513-472b-b2a7-891d68a3b549	11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group
group	CHEBI:24433	51-56
group	CHEBI:24433	161-166
growth factor	BAO:0002024	109-122
6734e552-d882-446e-a02f-c6bbe2eeb6ed	A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 110,034/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
breast cancer	DOID:1612	74-87
platelet count	CMO:0000029	130-144
hemoglobin	CHEBI:35143	163-173
3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19	None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes
3a4198ab-ae79-4200-b073-860b2e86813d	Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial.
history	BFO:0000182	21-28
breast	UBERON:0000310	122-128
327d67d2-35e7-45c3-958a-7955905f2d57	Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision
pulmonary embolism	HP:0002204,DOID:9477	30-48
excluded	HP:0040285	74-82
a1807b6a-6ee6-4c74-bf44-53d39c31c66f	the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group.
age	PATO:0000011	162-165
age	PATO:0000011	192-195
group	CHEBI:24433	166-171
group	CHEBI:24433	196-201
df39cd99-7291-4749-a7d5-ff760b7c3fc2	 cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial.
54a1eab3-1e8e-4c1c-a30f-f4d677a84c71	The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort.
rate	BAO:0080019	96-100
time	PATO:0000165	194-198
zoledronic acid	CHEBI:46557	230-245
cc6601cf-3aa0-44f7-8476-f3dfc34e7412	the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention.
7d60c7dd-fb79-4e95-a662-32de2036683f	In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2.
c12d4dba-17b9-45d6-9a3f-75be190b7795	the primary trial and the secondary trial recorded the same number of adverse events in their cohorts.
8aca5f0b-c998-4e51-9e53-e23294e61867	The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally.
88857141-6207-4828-b8d4-09d7cc4498c3	a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial
patient	HADO:0000008,OAE:0001817	2-9
organ	UBERON:0000062	31-36
month	UO:0000035	64-69
excluded	HP:0040285	80-88
9d9fc91e-b6a2-4ab8-bb28-a0a182574d90	Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study.
sunitinib	CHEBI:38940	0-9
day	UO:0000033	40-43
patient	HADO:0000008,OAE:0001817	54-61
duration	PATO:0001309	98-106
c43d1ac6-f3d2-44f6-870d-fb91f3365c5b	the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group.
group	CHEBI:24433	65-70
group	CHEBI:24433	227-232
f03664fa-20b3-4102-b1e2-fe901d028f65	women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial
95cb9c0a-0725-4108-aebb-f114f77b577c	less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products
726add6d-9f17-4e3e-a43e-8b391fbb953b	Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial.
lipoic acid	CHEBI:16494	65-76
duration	PATO:0001309	98-106
duration	PATO:0001309	213-221
8c07a493-66a5-4728-ae22-d6c45b2215a8	The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab
sunitinib	CHEBI:38940	112-121
9340e38d-37ce-4634-9f36-a747f964441c	All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care
frequent	HP:0040282	134-142
b20cbb69-8909-4a66-b47c-27192604d187	The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort.
rate	BAO:0080019	107-111
time	PATO:0000165	183-187
zoledronic acid	CHEBI:46557	219-234
b5f68d8f-0c92-4f58-9740-78556c039e58	Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial.
nut midline carcinoma	DOID:0060463	14-35
prostate cancer	HP:0012125,DOID:10283	58-73
breast cancer	DOID:1612	141-154
d475c476-8172-47a0-bf91-7ef5d0f6d081	the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID.
breast	UBERON:0000310	45-51
fulvestrant	CHEBI:31638	130-141
7f6d7fd9-8aed-472d-af54-b288d16c2135	Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome
syndrome	DOID:225	89-97
49c63fc5-be4b-4474-8bfc-0ddf9cf438db	There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial.
bronchopneumonia	DOID:12375	24-40
5887ed1d-aa43-4a18-be3a-9141b675d5af	Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation.
group	CHEBI:24433	40-45
group	CHEBI:24433	133-138
dermatitis	DOID:2723	178-188
fa6115aa-a765-4d03-9fd0-61c97d5e282f	all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group
function	BAO:0003117,BFO:0000034	76-84
function	BAO:0003117,BFO:0000034	120-128
group	CHEBI:24433	141-146
5a916856-536f-444d-87e7-1b2c032c0656	at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass.
patient	HADO:0000008,OAE:0001817	13-20
26145056-fdfd-4f2d-909e-be84fc53ede8	Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant.
aprepitant	CHEBI:499361	129-139
ceb02a85-73a3-4c00-823e-fb88bc91d239	Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day.
excluded	HP:0040285	12-20
day	UO:0000033	133-136
3cae8899-5172-460e-8ff1-e6e1c8a59f0b	the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine.
pain	HP:0012531	25-29
sulforaphane	CHEBI:47807	130-142
isothiocyanate	CHEBI:52221	158-172
urine	UBERON:0001088	190-195
8367e2fc-f384-43c0-af4e-d4ec41281b2e	Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2.
20493bc1-bda8-4255-a1d4-40cb499bd845	There was at least 1 case of infection in both the primary trial and the secondary trial
93eef0e8-7a40-452a-a61e-a9d671dcacbd	There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial
pancytopenia	HP:0001876,DOID:12450	53-65
patient	HADO:0000008,OAE:0001817	82-89
3d9a7121-da16-4e7b-a02d-1932f46cbb77	the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial.
anemia	HP:0001903,DOID:2355	43-49
pneumonia	HP:0002090,DOID:552	51-60
e2979c27-0eb6-487d-a940-646685e1934b	The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP.
5abfa152-2c23-40b4-ba00-b28336b8b8b5	Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial.
patient	HADO:0000008,OAE:0001817	10-17
251e979f-a7ba-4dea-afb7-01b9501ec7cf	96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group
ketorolac	CHEBI:6129	25-34
group	CHEBI:24433	41-46
group	CHEBI:24433	147-152
7eab2fc5-fd40-40bc-a960-90aafe45ef9e	A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 79000/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial.
year	UO:0000036	5-9
patient	HADO:0000008,OAE:0001817	14-21
breast cancer	DOID:1612	74-87
platelet count	CMO:0000029	130-144
hemoglobin	CHEBI:35143	161-171
a6299338-84c5-469d-9bd0-eff13b90a7eb	the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally.
5e5253e5-fd72-4f2b-84ba-b370545cd182	several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia.
neutropenia	HP:0001875,DOID:1227	37-48
pancytopenia	HP:0001876,DOID:12450	112-124
5e301f1c-087e-4ca4-b679-cc229d1c0d27	The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2.
0967b501-90dd-4ba4-bebc-8db1e9695431	 Alzheimer's patients are not eligible for the primary trial
8101ccf6-e6f4-43ba-b22f-9a13e2ddd279	The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it
paclitaxel	CHEBI:45863	22-32
paclitaxel	CHEBI:45863	99-109
gemcitabine	CHEBI:175901	55-66
group	CHEBI:24433	67-72
group	CHEBI:24433	127-132
292d0dd3-1b9c-4291-b367-0cc1666178db	the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy.
month	UO:0000035	105-110
ef1d6dfa-2cd0-4e19-99b7-a813d6952706	The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent.
86ed4db6-24fe-4a88-ba9b-6be3f98e0525	The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort
capecitabine	CHEBI:31348	16-28
lapatinib	CHEBI:49603	100-109
d71c6377-89da-457d-acbc-827be4ddb8e5	There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients
adverse event	OAE:0000001	26-39
affected	HP:0032320	68-76
74aebfd6-c201-4c6f-a7af-7e4e0de6b661	The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial.
adverse event	OAE:0000001	16-29
886a066c-520e-4454-bf20-43ad24b6baf9	Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial.
2a95f6b8-fbdd-47e6-949f-8aee18a2c605	Any japanese national can take part in the primary trial, or the secondary trial.
15d7d028-69c2-4e01-b85c-cff568f34cc1	anorexic patients are eligible for the primary trial.
fdadf425-1eaf-4e63-b034-29afcbe48baf	The only AE recorded in the primary trial was Stomatitis.
stomatitis	HP:0010280,DOID:9637	46-56
3ad9820f-4ef2-4624-b08a-b910adf25836	Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial.
ascites	HP:0001541	0-7
pneumocystis jirovecii pneumonia	HP:0020102	63-95
afdafe17-63a8-4fca-b923-a2bb964493d1	an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial
adult	EFO:0001272	3-8
patient	HADO:0000008,OAE:0001817	9-16
diffuse	HP:0020034	32-39
lung disease	DOID:850	52-64
excluded	HP:0040285	98-106
a0428861-8e0f-42ca-889f-b2546ae3dbe6	A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial.
e6e3ecde-9d81-41a2-849e-de26c1b9bafc	Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system.
f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2	the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery
surgery	OAE:0000067	100-107
surgery	OAE:0000067	214-221
81521795-13b4-46d4-a03e-51ab823e9756	Both interventions in the primary trial include trastuzumab
b29091a1-befa-4edc-9bc9-06263826bfdd	 Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+ Considering a mastectomy are eligible for the primary trial and the secondary trial
breast cancer	DOID:1612	45-58
593bde37-5962-441b-ac10-dbe3120cec99	less than 5% of patients in the primary trial suffered Aes
d85fd7f3-2765-407e-a8a3-49c19d9a4311	Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial.
cancer	DOID:162	31-37
b6902408-8d60-438b-bb38-416d4a4d76fb	None of the primary trial candidates have to perfom regular exercise as part of the intervention
part of	BAO:0090002,BFO:0000050	72-79
c484c0e8-0530-47cb-89dc-da4c4a7f4c0b	the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group.
group	CHEBI:24433	87-92
group	CHEBI:24433	185-190
7270c176-7bf2-4b0d-941d-912f5a3ed62c	0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients.
affected	HP:0032320	107-115
8be0e7b4-f74d-4205-a543-1247762bb467	The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial.
2c4acb3d-7009-4a19-ac0e-703a96740738	Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention
part of	BAO:0090002,BFO:0000050	68-75
401f0d8c-4f4e-4693-8baa-3ae8664480d3	patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial
breast	UBERON:0000310	102-108
67f1754a-420c-4605-a41d-784c4d1e77b0	there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	57-64
9727b232-81fc-42cc-bd06-05cc81a7453b	A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
1cdbbd44-21df-4279-9e3c-ff501f1361ec	the primary trial and the secondary trial report on the MTD of different interventions
mtd	BAO:0001248	56-59
78aec7ae-20b1-413b-9cb7-9757274ff1aa	Morbidly obese patients are eligible for the primary trial.
b3b66b49-6a4c-4c26-b46c-915ab45374ff	the primary trial patients receive higher doses of radiation therapy than the secondary trial participants
73876da9-0c79-43eb-9d1f-b7f2d729f43c	the primary trial had one test group and one placebo group, the secondary trial had 2 test groups.
group	CHEBI:24433	31-36
group	CHEBI:24433	53-58
group	CHEBI:24433	91-96
9c7521a7-87fc-4dc0-8c1e-5720836763e2	Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial
mirtazapine	CHEBI:6950	49-60
ffacecd7-caae-434a-866d-a3a25d4f00ac	The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection.
458419cf-ea6f-4939-ba2e-856b8d89b985	the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups.
7482499c-6836-4f68-83f4-4af09b14d566	There were no deaths or Hospitalizations in cohort 2 of the primary trial
a0d99371-52e5-4d30-81d5-ad65feba2e4e	Patients with measurable tumors in both breasts are excluded from the primary trial
excluded	HP:0040285	52-60
47bcd1c5-f95d-4e21-a999-4bd220c5b940	Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy
patient	HADO:0000008,OAE:0001817	6-13
capsule	GO:0042603	60-67
vorinostat	CHEBI:45716	71-81
cc411bc6-900e-4ef3-96ef-09f6e5565a18	children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial
excluded	HP:0040285	80-88
1943100e-196d-4022-a38a-9ae0dd816294	The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid than intervention 2.
d11356c5-cf48-40dc-aa23-46e71f564afd	There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial.
f8e8c733-3fc0-4699-814f-b5d505c71435	The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel
sunitinib	CHEBI:38940	101-110
paclitaxel	CHEBI:45863	154-164
dfea11ab-1a3f-4a76-9fae-96d486f76e10	Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial
history	BFO:0000182	24-31
myocardial infarction	HP:0001658,DOID:5844	83-104
stroke	HP:0001297,DOID:6713	111-117
transient	HP:0025153	120-129
abscess	HP:0025615	162-169
285b3905-8e47-4b26-8aa5-2d9d7f717a6c	Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections.
group	CHEBI:24433	41-46
92935ccc-f20d-4e27-9a5f-cb8d47162de6	candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial.
74308ad0-4b9d-4632-9580-5e280dedbc77	patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer.
breast cancer	DOID:1612	115-128
487dd970-35e7-4a7d-8bb6-e8fa98f574aa	Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial.
claustrophobia	HP:0025253	26-40
osteoporosis	HP:0000939,DOID:11476	45-57
1cda1a1d-3ca1-4838-9054-bcab763bb5d0	All of the Aes recorded for cohort 1 of the primary trial are related to mental health
9228fe22-ca97-4ca9-ad78-f8dba1ac27b0	Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial
lung	UBERON:0002048	96-100
lung	UBERON:0002048	129-133
breast cancer	DOID:1612	101-114
lung cancer	DOID:1324	129-140
aecd2958-c3b4-4d87-82f1-07add215b1e8	cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation.
dexamethasone	CHEBI:41879	52-65
dexamethasone	CHEBI:41879	93-106
590f240e-7499-432e-aa3c-f54eda69ed46	Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period 
active	PATO:0002354	46-52
561d1a70-6bd1-42f7-9e2a-73b9622a449c	the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group.
group	CHEBI:24433	31-36
group	CHEBI:24433	53-58
group	CHEBI:24433	91-96
group	CHEBI:24433	111-116
1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f	The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients.
adverse event	OAE:0000001	27-40
patient	HADO:0000008,OAE:0001817	52-59
patient	HADO:0000008,OAE:0001817	172-179
syncope	HP:0001279	117-124
c8235719-3fd8-43e9-8ba6-d99393220240	There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial 
age	PATO:0000011	61-64
837329c4-d046-4997-ad41-f230d3db7255	There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial.
e1040054-0fe6-4c92-be82-f2b5b79282a5	Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered.
suramin	CHEBI:180911	0-7
paclitaxel	CHEBI:45863	12-22
282c18a2-64b1-47cf-8563-db8db40dadb6	Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan.
f4e0551c-44e9-44f1-9a50-c65075a51715	There are no conditions on hepatic function for participants of the primary trial
function	BAO:0003117,BFO:0000034	35-43
cbba3546-5b88-42d0-882d-024d5f267d97	More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial.
palpitations	HP:0001962	5-17
ea1d804d-bac9-4ebd-a6bd-0705c988927f	The the primary trial intervention section does not outline a treatment cycle or any description of the treatment
fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a	There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma.
lymphoma	HP:0002665,DOID:0060058	148-156
17413685-69fd-453f-af49-29982a6c95b6	Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine.
vaccine	VO:0000001	81-88
vaccine	VO:0000001	141-148
influenza	DOID:8469	131-140
10292ba1-dd1f-4191-b534-331f39583181	Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial
excluded	HP:0040285	25-33
e78805f7-1b81-4cd9-a3c7-591886fd5d70	Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead
paclitaxel	CHEBI:45863	0-10
fulvestrant	CHEBI:31638	108-119
42857f32-4798-4767-a0c7-f74cdcab7a9b	participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2
duration	PATO:0001309	81-89
9c2adaba-1ac9-4a7c-a710-14ac7d2056fd	Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions.
af55082d-0ff1-419f-861f-80dbd05a9ade	the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients.
healthy	HP:0032322	137-144
cancer	DOID:162	149-155
3a0c092c-7e18-4108-ae66-552f7069831f	Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events.
3a452f00-375b-48c4-96dd-48986c0c0064	Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial
breast	UBERON:0000310	16-22
diameter	PATO:0001334	43-51
c94158fd-10f5-4142-a361-5b346ff2c295	There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial.
clostridium difficile colitis	HP:0032168,DOID:0060185	42-71
577c7755-64ae-4b78-bbe3-627cef6e3ece	More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery
breast	UBERON:0000310	103-109
lymph	UBERON:0002391	123-128
surgery	OAE:0000067	174-181
5b94480e-aa25-491e-ae37-a2b2939eafaf	All patients eligible for the secondary trial are also eligible for the primary trial.
494a4094-5a05-4c7d-b7a7-60baeb210e5a	There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial
5b13bca4-0354-4579-a868-d007bef0dbe1	The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group
neratinib	CHEBI:61397	4-13
group	CHEBI:24433	14-19
group	CHEBI:24433	83-88
rate	BAO:0080019	53-57
623db2b4-6824-42e4-9ad6-39cf3bf14dab	Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day.
day	UO:0000033	122-125
a793df3f-fa04-4d48-a2c6-006589d52e84	On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients
function	BAO:0003117,BFO:0000034	83-91
75961bc5-20b9-4161-83e0-a59429ce18e9	Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril
acute	HP:0011009,PATO:0000389	63-68
vomiting	HP:0002013	69-77
aprepitant	CHEBI:499361	99-109
dexamethasone	CHEBI:41879	111-124
d94a09b9-8201-43f3-9b27-cab0bc473af0	The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial.
6920329b-7559-415e-9346-c06909526421	There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial
neutropenia	HP:0001875,DOID:1227	30-41
cholelithiasis	HP:0001081,DOID:10211	45-59
85d61aaf-5255-4203-9ccf-f9c3da7a352e	Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial
cancer	DOID:162	55-61
22384b11-eb42-42da-86b3-dfed559ebb77	Only 2 patients in the primary trial did not have Recurrence-free Survival
0c73bdd4-7244-433c-8b5e-bf335f21701c	There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia
adverse event	OAE:0000001	30-43
eating disorder	DOID:8670	79-94
schizophrenia	HP:0100753,DOID:5419	99-112
b9b156ee-526a-49ac-aa99-78f02a24dbaf	Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial.
nut midline carcinoma	DOID:0060463	14-35
breast cancer	DOID:1612	102-115
3974c3ec-d3b5-4313-ae4b-4332ee5865ab	Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55
b358fb9c-1152-4e1a-88eb-743e965d58fc	Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial.
history	BFO:0000182	16-23
severe	HP:0012828	27-33
06b8d395-0fe7-4206-b118-5e478779cce0	There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs.
a911fcee-0621-4f06-a511-b8323ab8440c	Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies.
68f673a5-6ddf-487a-ad88-4903d92e1746	There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event.
patient	HADO:0000008,OAE:0001817	14-21
patient	HADO:0000008,OAE:0001817	77-84
adverse event	OAE:0000001	130-143
93bb8a0e-e84c-4730-b559-22d912103993	the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1.
lenalidomide	CHEBI:63791	39-51
lapatinib	CHEBI:49603	85-94
0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc	the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response 
time	PATO:0000165	30-34
102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed	There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial
mucositis	DOID:0080178	25-34
559c1faa-17b6-42c7-9f63-0cd58df39bfa	the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs.
drug	CHEBI:23888	36-40
drug	CHEBI:23888	107-111
fa586070-5821-4a70-9812-9d7c6e5df330	5 patients in the primary trial suffered 3 or more adverse events
8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de	All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week.
week	UO:0000034	74-78
week	UO:0000034	119-123
24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55	Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial.
ductal carcinoma in situ	HP:0030075,DOID:0060074	24-48
hypertension	HP:0000822,DOID:10763	66-78
excluded	HP:0040285	120-128
851e1a1b-0b8e-4aef-a7e3-f06c036fe537	cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2
b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52	Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions.
radiotherapy	OAE:0000235	56-68
9e3cf2a2-6713-4d07-adde-e334b49ca6ec	the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates
paclitaxel	CHEBI:45863	60-70
4493c1ed-668a-44d4-9b3e-767f597d4fa8	There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial
asthenia	HP:0025406	27-35
patient	HADO:0000008,OAE:0001817	81-88
b9074beb-a639-46ba-966b-b0db266efffc	The the primary trial intervention section dose not describe the method of administration, dosage or cycle.
017ff04d-5509-4f54-863c-10201351e15d	several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes.
vitamin d	CHEBI:27300	29-38
cd250e97-c2b4-48cd-bcbe-55ea06fa9662	A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial.
a1a3cda8-7324-4270-aaf9-51ad1b40be07	the secondary trial recorded 11 more Aes than the primary trial
25551d37-108d-497a-8e75-825d8d707190	Patients with measurable bilateral breast cancer are eligible for the primary trial
bilateral breast cancer	DOID:6741	25-48
bc7b62ad-797e-419e-b5f9-888117aedf6b	There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial.
hypothermia	HP:0002045	37-48
confusion	HP:0001289	53-62
5261c924-d9ef-43ed-8f2a-6c5b1552cc62	Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements.
active	PATO:0002354	46-52
b5e896cf-e971-4fac-8dc6-a19e2c2d0a72	There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial
age	PATO:0000011	57-60
2bf9e0d9-1195-4c03-b2bc-d491ff1cd174	36.36% of the primary trial patients suffered an increase in Blood bilirubin.
increase	BAO:0001251	49-57
blood	UBERON:0000178	61-66
1bf99d45-84a7-41cb-8263-d1ccb489bc66	The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial
eyelid	UBERON:0001711	73-79
chest pain	HP:0100749	91-101
adfed785-8da6-4bf4-836f-2dfadf0510b6	the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants.
523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6	49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group
group	CHEBI:24433	52-57
group	CHEBI:24433	162-167
growth factor	BAO:0002024	110-123
2a0b1a83-299d-404d-96e5-67ee65173dde	the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally.
breast	UBERON:0000310	45-51
25cbaa44-4715-417b-9bd0-12fef06053b8	less than 10 patients in the primary trial suffered Aes
0f31bc6a-a228-49c2-afff-4177ef850272	There were more participants in the primary trial than in the secondary trial
bf3034ec-679a-42d1-9d24-69b51c602233	Gender is not a determining factor for eligibility in the primary trial or the secondary trial
fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec	the primary trial and the secondary trial do not have any recorded adverse events for their participants.
5e6797ef-370c-4b35-9e1d-37e694b538a6	25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression 
pleural effusion	HP:0002202	54-70
disease	DOID:4,OGMS:0000031	81-88
28a88ea8-4cea-404c-9ad7-cb1be9c19d7f	Paclitaxel is not used in either of the primary trial interventions
paclitaxel	CHEBI:45863	0-10
59a0bff2-c254-45f1-a6ae-2d847777db94	the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response 
time	PATO:0000165	30-34
44412911-1f34-4841-a795-86eed5a209d7	All Infections and Fever cases in the primary trial were for patients in cohort 1.
fever	HP:0001945	19-24
505ccc8c-b07a-4902-b8c3-4d3b4891779a	Patients in the primary trial will need to receive several injections
58614e8d-770e-4bfe-b74b-e2d429ef072f	Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial
d118efb5-ea31-49ca-8e20-686c85081e94	Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants
cholelithiasis	HP:0001081,DOID:10211	0-14
5a181517-dbdc-4598-8955-ca1bfa380fa9	The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim.
drug	CHEBI:23888	59-63
drug	CHEBI:23888	151-155
zoledronic acid	CHEBI:46557	168-183
4adbcbcc-ae43-46af-a072-815d1e788f29	patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial.
excluded	HP:0040285	106-114
10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5	In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time.
memantine	CHEBI:64312	54-63
frequency	HP:0040279	106-115
duration	PATO:0001309	129-137
time	PATO:0000165	141-145
bd5d8368-5c1d-41b8-9fb3-f174da18744f	All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period
month	UO:0000035	90-95
d1a7cbaa-161a-4675-b8b7-67ae364be364	Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies.
574106ef-1b9c-4540-a89f-5100a9bbe798	African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study.
duration	PATO:0001309	115-123
21c021d2-764d-4028-b945-2aeb525b9888	the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR.
aefb2cc5-3101-416b-bae4-c9a1e7d8f39e	Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial.
recurrent	HP:0031796	0-9
graft-versus-host disease	DOID:0081267	24-49
diffuse alveolar hemorrhage	HP:0025420	88-115
320ec115-31c3-47bf-a819-93d514b91eb3	None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation.
group	CHEBI:24433	28-33
group	CHEBI:24433	121-126
dermatitis	DOID:2723	166-176
f45b251f-2fec-44b7-8fc0-dd0d06a44d3b	In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants.
d54a3e9d-5602-4cc3-934e-717f1da39792	The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine
pain	HP:0012531	48-52
intensity	PATO:0000049	53-62
bone mineral density	CMO:0001226	136-156
ce8a4f39-efff-4fd3-b850-4fc5c30270ef	the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections.
frequency	HP:0040279	80-89
9d94e597-591d-409e-a8e2-b205a83533a5	in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy
hypertension	HP:0000822,DOID:10763	98-110
7e271bbd-26e8-422e-be5c-54d294da815a	Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial.
carcinoma	HP:0030731,DOID:305	36-45
breast	UBERON:0000310	53-59
estrogen	CHEBI:50114,BAO:0000760	68-76
progesterone	CHEBI:17026	84-96
receptor	BAO:0000281	97-105
6e4be816-3da7-4def-ab23-2a4fda805cd0	laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial.
lateral	HP:0025275	44-51
90cecb95-9f89-4747-81c3-96545edaf3f4	No two patients in the primary trial suffered the same type of adverse event.
adverse event	OAE:0000001	63-76
137bb76f-a37e-4339-af7e-f0c647a01baa	the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort.
disease	DOID:4,OGMS:0000031	70-77
death	OAE:0000632	93-98
capecitabine	CHEBI:31348	122-134
c41ed5cf-4629-4a4f-b564-197d705ec9cc	There were 0 adverse events in the primary trial and the secondary trial
956a23c9-f76f-4492-9f00-acdbaf6ac083	The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial.
blood	UBERON:0000178	70-75
bone marrow	UBERON:0002371	80-91
b87ab44e-6cbe-4567-98ff-bd820aa7edeb	13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases
breast cancer	DOID:1612	57-70
e2e8bb00-df98-49c2-a81b-e18ae21516aa	The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection.
6b3619d3-21ea-437e-bb0f-f124cf636ca5	the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15
peptide	CHEBI:16670,BAO:0000325	48-55
vaccine	VO:0000001	56-63
0c03c804-4144-4d84-b740-8f6040f15acc	A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial
year	UO:0000036	5-9
female	PATO:0000383	14-20
patient	HADO:0000008,OAE:0001817	21-28
breast cancer	DOID:1612	79-92
c08aa0d8-5505-438c-b53a-934bd2ee570d	the primary trial does not report any results for the LBH589 and Lapatinib cohort.
lapatinib	CHEBI:49603	65-74
0a1cb41e-a5f8-42ca-bec7-f9bc1291037c	The dosage of Zoledronic Acid in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial.
zoledronic acid	CHEBI:46557	14-29
ddf4fc68-7920-4212-ac8b-7453ebeb49fb	Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures.
positron	CHEBI:30225	82-90
tomography	BAO:0002525	100-110
tomography	BAO:0002525	122-132
09879638-e324-4f5d-a45e-f62f7e06f301	children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial
excluded	HP:0040285	141-149
bc50160f-7490-4c30-b373-9474707b02b3	0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections
affected	HP:0032320	107-115
ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31	Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial
7d818afc-93da-4098-a0f0-558bc0095687	Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer.
female	PATO:0000383	0-6
cancer	DOID:162	7-13
cancer	DOID:162	117-123
cancer	DOID:162	191-197
age	PATO:0000011	32-35
breast cancer	DOID:1612	184-197
e04edb9d-dc0e-44c4-abb9-3260b400e265	Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure.
function	BAO:0003117,BFO:0000034	71-79
6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0	There are 7 more participants in cohort 2 of the primary trial than in cohort 1
e63ac45b-c34b-4007-820a-30202893fc6f	There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation .
colorectal cancer	DOID:9256	107-124
ff11f88f-a4cb-481e-bf56-afa5c0adda19	the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial.
patient	HADO:0000008,OAE:0001817	71-78
29bed237-ccbb-460b-a50b-fbdc9e52fdd1	All AE types in the primary trial affected less than 10% of patients
affected	HP:0032320	34-42
88951a9e-179e-4284-9f98-141eb3d76369	Aes were not recorded for the primary trial or the secondary trial.
71698d59-3bbe-4e8f-85c8-bf2110727155	Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2
affected	HP:0032320	41-49
970f06b2-0935-4cde-a070-ddd7adb8ed5e	Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial
female	PATO:0000383	82-88
d0168033-35eb-4032-b6e5-f81d9d3a9f7a	Patients in the primary trial that didn‚Äö√Ñ√¥t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy.
cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8	There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial.
3d100b36-5765-4953-b072-b06f38b6958c	The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group
paclitaxel	CHEBI:45863	22-32
paclitaxel	CHEBI:45863	99-109
gemcitabine	CHEBI:175901	55-66
group	CHEBI:24433	67-72
group	CHEBI:24433	127-132
f0ca21dc-bf98-4c8b-b08e-d0821905846a	Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list.
acupuncture	OAE:0002430	0-11
lymphedema	HP:0001004,DOID:4977	70-80
b88356ec-038f-4f5c-bf14-750059dbba4f	The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope
adverse event	OAE:0000001	27-40
patient	HADO:0000008,OAE:0001817	52-59
syncope	HP:0001279	117-124
56e9308b-f718-4831-8e56-4b18982e4a2c	the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial
patient	HADO:0000008,OAE:0001817	50-57
86ee12d2-2095-4ece-a7d6-f9494b51f3a6	the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention.
acupuncture	OAE:0002430	89-100
8ef6757e-e789-4a70-9cf3-e2e8050c9f15	the primary trial and the secondary trial evaluate different patient characteristics in their results.
patient	HADO:0000008,OAE:0001817	61-68
52d4cfdf-7677-4f4c-8020-4f5271393df9	Patients participating in the primary trial receive oral medication twice a day for a full month.
day	UO:0000033	76-79
month	UO:0000035	91-96
a8932849-e870-422e-a81a-1b43d9622082	the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group
ketorolac	CHEBI:6129	4-13
group	CHEBI:24433	20-25
group	CHEBI:24433	114-119
06a1adac-dee0-4d9b-83c6-0996391e40d0	13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine 
vaccine	VO:0000001	124-131
c2d6b8ba-8238-49b7-b9a1-de2ffdabe324	Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria
496667f2-e493-4b4e-a257-7b8de3833e8b	The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days.
trabectedin	CHEBI:84050	16-27
47512f16-9809-4150-a101-1fb7256c5bf3	the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine.
sulforaphane	CHEBI:47807	138-150
isothiocyanate	CHEBI:52221	166-180
urine	UBERON:0001088	198-203
d904b234-fed6-473e-bd40-8f37f4a4e440	the primary trial and the secondary trial do not test the same drugs
90c519e9-7981-4a72-af6a-cc032657458a	The the primary trial intervention section requires surgical and imaging procedures.
d9e7c0cc-0850-4a8e-b389-092dfdc623fc	Patients with histologically documented metastatic SCBC are excluded from the primary trial.
excluded	HP:0040285	60-68
05fbffcf-c1a0-40f9-95dd-8e9010005773	the secondary trial and the primary trial report results from one patient cohort.
patient	HADO:0000008,OAE:0001817	66-73
7814620b-23de-463b-8fd1-efdf51ce26b3	an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial
adult	EFO:0001272	3-8
patient	HADO:0000008,OAE:0001817	9-16
ae548af6-b401-4dac-9824-50b2a566e7bd	18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation.
excluded	HP:0040285	18-26
age	PATO:0000011	95-98
range	LABO:0000114	99-104
a60074c0-d7a6-47cc-b980-ee1c0a791f66	Both cohorts of the primary trial receive the same doses of Abraxane
d9d506ef-20ed-44e2-9809-07cb0772535b	All Infections and Infestations cases in the primary trial were for patients in cohort 1.
1defe036-8290-4a01-bec7-f75305d1e88e	Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure.
time	PATO:0000165	93-97
1fe68175-6ac4-4439-818f-94758e6bd306	Patients in the primary trial that didn‚Äö√Ñ√¥t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions.
paclitaxel	CHEBI:45863	56-66
paclitaxel	CHEBI:45863	127-137
fac10570-e1ed-4b0a-b847-55eb25265d25	1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia.
neutropenia	HP:0001875,DOID:1227	30-41
pancytopenia	HP:0001876,DOID:12450	106-118
152fc619-bbb0-40ff-aa3e-5722f62f6a84	Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer.
228308ea-2483-4311-a975-ca974ff797c6	Nobody taking part in the primary trial suffered a UTI
eca5c391-f479-448d-bff8-313a7df673b4	the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts
cyclophosphamide	CHEBI:4026	58-74
paclitaxel	CHEBI:45863	76-86
patient	HADO:0000008,OAE:0001817	114-121
17660aaf-9218-4119-b00c-f3b863718e97	Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention
291150cd-0d45-46c7-9a44-d781098bc3eb	Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer.
female	PATO:0000383	0-6
cancer	DOID:162	7-13
cancer	DOID:162	119-125
cancer	DOID:162	197-203
age	PATO:0000011	32-35
breast cancer	DOID:1612	190-203
403ad287-6e25-4db0-a66b-fe4a7f15a983	A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial.
patient	HADO:0000008,OAE:0001817	2-9
diameter	PATO:0001334	43-51
c389c3cc-2e76-4219-996d-3aa5a925fec7	the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement.
6f0571f4-e1da-4732-9bdf-8c07bea059c1	the secondary trial and the primary trial report their results using the same units of measure.
c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8	a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial
breast cancer	DOID:1612	63-76
b16d4167-cb81-44c0-b20d-d1ecbf0bc094	the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein
tube	BAO:0010014,UBERON:0000025	140-144
inserted	BAO:0000641	145-153
vein	UBERON:0001638	161-165
36cbd8dd-9c77-496c-ab43-af1942c86339	Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin
carboplatin	CHEBI:31355	73-84
50dae016-a6b4-4ee6-a66a-bf35587cd835	On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years.
patient	HADO:0000008,OAE:0001817	11-18
patient	HADO:0000008,OAE:0001817	86-93
c63468c0-324f-4528-b83f-a588ccf7b680	Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial
diameter	PATO:0001334	39-47
ef2af81d-e19c-49c9-8ff0-309b87eb6f38	the primary trial only has a single adverse event recorded for its patient cohort.
adverse event	OAE:0000001	36-49
patient	HADO:0000008,OAE:0001817	67-74
4714a31c-c7ca-49e2-aa71-6665b65ed04f	Morbidly obese patients can be eligible for the primary trial and the secondary trial.
570b88e9-5036-4ea8-80db-0f48696700af	All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants
f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b	Most patients in the secondary trial and the primary trial did not suffer any adverse events
8d685159-80a2-4b2c-8ca3-066d03e1cf66	There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial
mucositis	DOID:0080178	25-34
5e93b7d7-89d9-47cd-98b4-5897823889fa	cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine.
chloroquine	CHEBI:3638	139-150
2e42ac97-e353-4bbc-b61e-391e0c092689	The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2.
0585f6bd-d582-4fc9-b96b-1355fa083e33	the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans
surgery	OAE:0000067	126-133
4f1bafd9-361f-4981-b6fd-46af736141b4	The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses.
c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b	On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months
0bb34f7b-d21a-4057-876a-25c722e6d50e	97% of patients in the primary trial did not experience any Adverse Events
3f15d923-bf66-4188-8714-c9ae4921de1f	the secondary trial and the primary trial share at least one inclusion criteria.
9562c377-c748-46d7-a5f2-eb492d20e477	there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial
hypertension	HP:0000822,DOID:10763	22-34
dehydration	HP:0001944	36-47
dyspnea	HP:0002094	52-59
1e24905e-7bf9-4a79-8157-8948f108ecb7	Neiter of the primary trial cohorts receive any invasive surgery or Neratinib 
surgery	OAE:0000067	57-64
neratinib	CHEBI:61397	68-77
57656a6d-8e1c-4cb8-b80d-605174d0577c	Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial.
cancer	DOID:162	4-10
patient	HADO:0000008,OAE:0001817	11-18
fibromyalgia	DOID:631	41-53
anemia	HP:0001903,DOID:2355	79-85
c5ece9f7-9119-4fa2-b60d-f2f15c68ae02	Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial.
recurrent	HP:0031796	0-9
graft-versus-host disease	DOID:0081267	24-49
diffuse alveolar hemorrhage	HP:0025420	80-107
8f8be6b6-df75-4757-bc64-b2fbc8849f70	There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial.
group	CHEBI:24433	43-48
group	CHEBI:24433	91-96
520f44e8-b74b-44a6-a7cf-496275847af1	Both cohorts of the primary trial recorded 0 Aes
0c902de2-30b5-4ab8-9739-70be987d043a	25% of cohort 2 patients in the primary trial suffer Increased pleural effusion
pleural effusion	HP:0002202	63-79
8b98421d-1cec-41bd-b25e-2e73c362193a	the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial
condition	PDRO:0000129	40-49
patient	HADO:0000008,OAE:0001817	65-72
62441471-f329-4540-9d4e-dc34c4d08d59	the secondary trial candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial
d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f	there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial 
cf45d975-0c29-4cf3-8f21-c245482a2b32	the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions
fb011e19-d4fb-4e6c-b7c9-7a7238f78970	Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria)
fd800c89-d30c-4a9a-970b-5385deeab52f	There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial.
d0212d75-c952-4ad3-ae36-bbf675eae985	Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril
acute	HP:0011009,PATO:0000389	63-68
vomiting	HP:0002013	69-77
aprepitant	CHEBI:499361	99-109
dexamethasone	CHEBI:41879	111-124
5d98b3df-684a-466d-93da-5a672f602db6	the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib.
sunitinib	CHEBI:38940	120-129
61a6a476-9283-4cde-89e7-5f1405f690c1	Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month.
lapatinib	CHEBI:49603	67-76
day	UO:0000033	85-88
month	UO:0000035	100-105
bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b	the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs)
fabf3f7a-48df-4940-93e2-8cbe976c4246	there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial
hypertension	HP:0000822,DOID:10763	22-34
edema	HP:0000969	36-41
dyspnea	HP:0002094	46-53
e8351b8b-d707-4766-b875-777557f0653f	Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial.
5dea6bbb-13c3-470c-98a6-3879f17de8c7	the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort.
5c00eee7-bb33-45e5-97c6-4cfc34946cdf	the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment
drug	CHEBI:23888	36-40
drug	CHEBI:23888	116-120
c3f4b547-8d11-42ba-800c-7ccbe1283741	Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial
breast cancer	DOID:1612	0-13
estrogen	CHEBI:50114,BAO:0000760	28-36
progesterone	CHEBI:17026	47-59
451c8e9e-03c1-4b7a-9b84-5129c5623f1b	candidates for the primary trial must have breast cancer and require hormonal treatment.
breast cancer	DOID:1612	43-56
7723c9e5-e80e-4ef6-b56d-ee26f8423d90	The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine
severity	HP:0012824	41-49
nausea	HP:0002018	61-67
bone mineral density	CMO:0001226	160-180
b6b719ca-e7f3-4254-a1a0-2946acbcd2fd	The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group.
group	CHEBI:24433	19-24
group	CHEBI:24433	135-140
diameter	PATO:0001334	96-104
zoledronic acid	CHEBI:46557	114-129
b3f59657-9278-41be-b740-433b0d38fdd5	Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial
m1	CHEBI:34826	42-44
bcc9a793-5002-4cd9-a5b7-af5a1ceca35a	candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments.
colon cancer	HP:0003003,DOID:219	43-55
3a141563-97b8-4154-8c9c-f1f551ec7969	Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses
64441aad-b959-41bb-aa81-2f594d00b70c	candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests.
ct	BAO:0002125	152-154
blood	UBERON:0000178	164-169
5fcf6210-c07a-4b8e-9944-c2f0714e4d69	All the primary trial participants receive lower doses of drugs than the secondary trial participants
05530068-7a95-46f6-88d2-84e53ee2ff35	General symptoms are the most common AE recorded in the primary trial
40fc3a97-0a5d-4f19-ba94-7c4668d0538d	Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial
f0f8a0a6-1148-4592-a9b4-27c005038900	participants in the primary trial receive 4 different drugs throughout the study duration.
duration	PATO:0001309	81-89
2cde3c46-f21a-4177-afc8-94f851854b98	There was at least 1 recorded gastro-intestinal adverse event in the primary trial
adverse event	OAE:0000001	48-61
b3679900-ab99-4a84-83e0-fc1122a43beb	Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial.
month	UO:0000035	114-119
excluded	HP:0040285	143-151
21afdaec-2db5-42b3-b201-b2dee4e23cb7	the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs.
frequency	HP:0040279	80-89
b9b69888-f771-4a3a-b6f0-825510997cca	cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2
6d7c7740-c399-4d73-82c8-2ef0d4739341	Cohort 1 of the primary trial did not report any Aes
15577bb6-3b4d-4373-ae58-eb0bf0c34954	warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial.
warfarin	CHEBI:10033	0-8
315f4573-d5b1-4cbc-9efb-74c27a98dc6d	Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial.
breast adenocarcinoma	DOID:3458	47-68
fe6baecc-71eb-4b15-ba15-66d57539c702	The same perecentage of patients suffered adverse events in both cohorts of the primary trial
b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf	The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death 
patient	HADO:0000008,OAE:0001817	4-11
disease	DOID:4,OGMS:0000031	82-89
death	OAE:0000632	105-110
f9e4988c-a325-40bc-8220-e7d0c404fd37	None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort
adverse event	OAE:0000001	23-36
affected	HP:0032320	73-81
patient	HADO:0000008,OAE:0001817	109-116
ef2352dc-a976-47c6-91cd-6666e3f7b55a	the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours.
mean	BAO:0002173	141-145
sleep	GO:0030431	146-151
time	PATO:0000165	152-156
ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac	More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2.
9cd25233-1d76-4d0d-a571-ce8fee279757	Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial.
0c27bcc9-3108-4d4a-901a-22718c22d288	The majority of patients in the primary trial experienced complete response by week 24.
week	UO:0000034	79-83
464e2cd9-6c59-4692-a3fc-083c374f4a5c	Both interventions in the primary trial include the same dose of Paraplatin
438a978d-ac7e-4260-bb24-d2129cb3dfc6	Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial
severe	HP:0012828	24-30
insomnia	HP:0100785	31-39
schizophrenia	HP:0100753,DOID:5419	44-57
excluded	HP:0040285	62-70
863f7074-fb4b-4c82-9e30-bb785f85f816	The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine
eeb18145-fc5f-41d7-bce3-245d21000e7b	Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) .
lapatinib	CHEBI:49603	52-61
ad5ca7e8-3e5d-43b8-9618-99f56fc70290	There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed.
3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5	The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month.
glass	CHEBI:131189	82-87
ibrutinib	CHEBI:76612	192-201
month	UO:0000035	245-250
7dd6b446-5585-4660-8bc7-e9811af66268	Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial.
f45bbf0b-4acd-4166-81a6-6b407cff87ca	the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group.
group	CHEBI:24433	72-77
group	CHEBI:24433	170-175
b23563cf-e6c4-4279-92b7-39d5e4de96d2	None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets
d921df56-8a29-45a9-bb0b-66ba14dbc193	Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial.
excluded	HP:0040285	150-158
006c9dd6-c568-4497-81b7-c954568a3b4a	Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead.
breast cancer	DOID:1612	0-13
cancer	DOID:162	7-13
cancer	DOID:162	117-123
585b42d5-c81a-482a-a6bf-b7db6c6edcfb	Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention.
cervical cancer	DOID:4362	8-23
620b6390-df07-45fe-9ef9-55a32521c740	Diarrhoea was more common for the primary trial participants than the secondary trial participants
eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a	100.0% of cohort 1 of the primary trial suffered some kind of adverse event
adverse event	OAE:0000001	62-75
9334239a-f4f1-4192-a35d-93c25c41328d	the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na‚àö√òve participants in the secondary trial receive sunitinib.
sunitinib	CHEBI:38940	73-82
sunitinib	CHEBI:38940	137-146
feca7444-9108-45e9-b722-4f0a207376c7	Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial.
vitamin d	CHEBI:27300	16-25
excluded	HP:0040285	41-49
2e2a005f-232f-457a-880e-c3950bc58df6	The interventions in the primary trial and the secondary trial include completely different drug-based treatments.
b95564b8-cdbe-45d0-be91-764d6768e5f9	the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel
paclitaxel	CHEBI:45863	60-70
2ce0822a-fcf8-4010-950c-0d3a8dc2cb00	Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial.
allergy	HP:0012393	29-36
cephalosporin	CHEBI:23066	40-53
levofloxacin	CHEBI:63598	86-98
celecoxib	CHEBI:41423	102-111
e6bba244-c154-4143-a5f2-5f8b1c304a97	 Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial.
a5657dcd-1ee5-44f6-bb21-e718259c4b2e	There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation .
atrial fibrillation	HP:0005110,DOID:0060224	101-120
8180d5e0-b284-45fe-a390-0c3a54dc663f	cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV.
chloroquine	CHEBI:3638	152-163
87fda661-4348-4078-b3e7-915893241ab0	Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial
suramin	CHEBI:180911	0-7
paclitaxel	CHEBI:45863	12-22
4bc60955-6137-4496-b780-5fb8e90dc3ed	maculo-papular Rash was a common adverse event for the primary trial participants.
adverse event	OAE:0000001	33-46
7ad6c209-8893-4a2d-963d-24666ef93a80	Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2.
positron	CHEBI:30225	82-90
tomography	BAO:0002525	100-110
tomography	BAO:0002525	122-132
a06166e6-12c9-49ba-ad3a-7fcfb5234174	the secondary trial and the primary trial have completely unrelated outcome measurements.
73feb437-66f3-44fd-8d9c-ab3204e6eac3	Several recorded Aes in the primary trial occurred to cohort 1 patients
927d72b0-1f55-4803-9a86-40838c08f923	the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid.
month	UO:0000035	105-110
19e0531d-7907-46b0-ab0c-e616746498e9	Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine.
group	CHEBI:24433	0-5
dexmedetomidine	CHEBI:4466	50-65
dexmedetomidine	CHEBI:4466	132-147
fc281ab7-f956-47d7-a938-8778fef1bca0	Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study.
group	CHEBI:24433	41-46
6261a694-0407-4840-8a87-3a0c6f9dea4f	the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX.
patient	HADO:0000008,OAE:0001817	36-43
patient	HADO:0000008,OAE:0001817	151-158
pregabalin	CHEBI:64356	72-82
9730b1a6-e9cd-4fd6-b1e4-9916b5903c63	In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort.
2fb3af20-adda-4fee-860a-ce376d3a0bb2	In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24
stable	HP:0031915	59-65
disease	DOID:4,OGMS:0000031	66-73
week	UO:0000034	77-81
week	UO:0000034	90-94
week	UO:0000034	140-144
f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d	the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts.
patient	HADO:0000008,OAE:0001817	100-107
dd27a6e7-3b83-4a84-bc40-5ba39617a1c1	Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both.
excluded	HP:0040285	76-84
113abff0-a728-40a6-b637-8bd60a53e626	Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2.
1cb125fb-0be1-49c6-b68b-64b525278c9c	Across both the primary trial and the secondary trial only one death was recorded in the adverse events.
death	OAE:0000632	63-68
fd0b22b0-c86d-4460-bf53-310901404ef5	All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+
c0151b24-14ab-4837-965d-88bb8115a560	The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death 
patient	HADO:0000008,OAE:0001817	4-11
disease	DOID:4,OGMS:0000031	106-113
death	OAE:0000632	129-134
1d66459b-4624-4ea0-9cda-992c4146a454	Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial.
gabapentin	CHEBI:42797	21-31
pregabalin	CHEBI:64356	35-45
result	BAO:0000179	51-57
73981f59-887e-4778-a78a-0bf7b7a405b7	the primary trial has 4 more adverse events recorded than the secondary trial
dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6	There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial
ct	BAO:0002125	33-35
5599d5d8-3a7b-41ce-a00c-6e0b609b618d	100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event
adverse event	OAE:0000001	77-90
84942825-f636-4dcf-af2e-172012c0cc9d	cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel
cyclophosphamide	CHEBI:4026	55-71
cyclophosphamide	CHEBI:4026	132-148
eribulin	CHEBI:63587	77-85
e4b448ba-15ad-4cf8-9343-782d45166891	the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement.
drug	CHEBI:23888	64-68
27aec260-8dcc-4611-8389-dc9c10d3518d	Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average.
tamoxifen	CHEBI:41774	41-50
surgery	OAE:0000067	86-93
surgery	OAE:0000067	130-137
breast cancer	DOID:1612	116-129
diameter	PATO:0001334	150-158
943f62ca-d87c-4a5e-9355-6750d7d9b58f	The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial.
tamoxifen	CHEBI:41774	101-110
e53898b8-422f-4317-b2f6-c487409b0750	In total there are less cases of anemia in the primary trial than in the secondary trial.
anemia	HP:0001903,DOID:2355	33-39
7b819ac1-92e6-41ce-881c-0f4581a690ee	There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial.
c09c08d5-189f-4e15-acb8-2c3cb235aaa6	The same number of Aes were reported for both cohorts in the primary trial
99a6cb19-b6d8-4cb7-84e1-be559854caa6	All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks.
70539b18-50b0-43f7-b676-2143de2dc3e8	the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts
cyclophosphamide	CHEBI:4026	58-74
patient	HADO:0000008,OAE:0001817	84-91
52b055fd-9e0d-41ad-9eb7-1a724cbc0112	There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial.
group	CHEBI:24433	62-67
group	CHEBI:24433	152-157
group	CHEBI:24433	170-175
dcfc0053-b963-4542-ae02-228d3d2bd98e	The Interventions in the primary trial included different medications but are administered through the same routes.
f706897d-d54e-4449-8bc7-da0bd6fbad01	candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial
c39ec45a-1664-49aa-8356-abbecf045001	over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events
eb555e01-0a12-45a1-99ad-7d7dafbe8912	Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle.
c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b	the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial
intestinal perforation	HP:0031368,DOID:2074	46-68
094e7aec-88db-4ad0-b995-ece8587fd48b	There are no X-rays, transendocardial injections, CT scans or MRIs included the interventions of the primary trial and the secondary trial
ct	BAO:0002125	42-44
ct	BAO:0002125	50-52
20c98ba5-ca61-4afe-af57-6de08705a5cd	the secondary trial and the primary trial use different outcome measurements and units of measure.
58fa0ef4-0355-42bc-8378-fef98752b05e	Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial.
lipoic acid	CHEBI:16494	65-76
duration	PATO:0001309	98-106
duration	PATO:0001309	258-266
b033d45a-c039-42de-a073-3c051c6f1e3c	Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR).
lapatinib	CHEBI:49603	52-61
75c55f70-aa52-4794-aae7-3a355f1a76e9	Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial
breast cancer	DOID:1612	0-13
estrogen	CHEBI:50114,BAO:0000760	28-36
progesterone	CHEBI:17026	47-59
070ba2da-932a-4a62-861e-3f2c89630b4d	Most the primary trial candidates suffered from some kind of eating disorder during the study duration
eating disorder	DOID:8670	61-76
duration	PATO:0001309	94-102
76d498ce-037c-4f7e-8cbb-450d8f6019ec	patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic.
dfd8e736-5ef2-4d36-b124-9382e72f982d	the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group.
group	CHEBI:24433	65-70
group	CHEBI:24433	171-176
hot flashes	HP:0031217	89-100
day	UO:0000033	105-108
a4a2c0ba-3fa9-4fad-9258-7e517ae85e25	alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day.
excluded	HP:0040285	23-31
day	UO:0000033	144-147
e8e3fedb-075d-440e-bf2e-baec76f96cca	Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial
lung cancer	DOID:1324	85-96
lung cancer	DOID:1324	111-122
b53a2698-dfb0-416d-9f3e-2e800a360b3e	the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX.
patient	HADO:0000008,OAE:0001817	36-43
patient	HADO:0000008,OAE:0001817	136-143
pregabalin	CHEBI:64356	72-82
cd067ee2-ed1d-403b-aa50-d61a3399fda3	after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression 
month	UO:0000035	8-13
tamoxifen	CHEBI:41774	30-39
8b50bdc1-1722-403b-a854-adeaacd02acb	Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial.
history	BFO:0000182	16-23
history	BFO:0000182	76-83
severe	HP:0012828	27-33
